Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
- NAFLD (Non-alcoholic fatty liver disease) has become the most common cause of liver
disease in Western countries (hepatic manifestation of insulin resistance);
- NAFLD represents a cardiovascular risk factor;
- Lifestyle modification(weight loss)is the effective medical treatment recommended for
NASH (Non-alcoholic Steatohepatitis);
- Ezetimibe could represent a novel safe treatment for NAFLD (Patel 2006. Here the
investigators propose a Randomized Controlled Pilot Trial to evaluate the addictive
effect of ezetimibe on liver histology, biochemical and sonographic parameters in a
small (n.40) number of NASH patients randomized for 12 months in two arms: lifestyle vs
lifestyle+ezetimibe.